PMC8511520_01
Facial eczema prior to (A) and after (B) starting treatment with dupilumab. (C,D) Show lesions on the right leg and right ear, respectively, prior to dupilumab treatment. Although corresponding images for (C,D) after treatment were not captured, the lesions seen prior to treatment resolved after dupilumab treatment.
fped-09-646997-g0001.jpg
PMC8511520_01_fped-09-646997-g0001.jpg
F1
Furthermore, the patient was able to discontinue topical and systemic steroids (Figure 1).
Timeline illustrating the development of our patient's clinical phenotype and improvement following dupilumab. Interventions are indicated in red. HSV, herpes simplex virus; IgE, immunoglobulin E; IVIG, intravenous immunoglobulin; MRSA, methicillin resistant Staphylococcus aureus; TMP/SMX, trimethoprim/sulfamethoxazole.
fped-09-646997-g0002.jpg
PMC8511520_01_fped-09-646997-g0002.jpg
F2
A timeline illustrating the development of our patient's clinical phenotype and treatment is summarized in Figure 2.